Anders Ståhlberg


Anders Ståhlberg, Ph.D, is a Swedish biomedical scientist and professor of Clinical Genomics at the University of Gothenburg. He is an investigator at the Sahlgrenska Cancer Center and heads the translational Genomics Platform at Sahlgrenska University Hospital. His research focuses on developing and implementing new cancer diagnostics, particularly using liquid biopsies and single-cell sequencing.
WWW cancercenter.gu.se/resear...

Education

Anders Ståhlberg holds a Master of Science in Chemistry and Bioscience and a Ph.D in Chemistry and Bioscience from Chalmers University of Technology. Following his Ph.D., he completed postdoctoral research in the United States, with a focus on human embryonic stem cell biology and tumor reseach. During this time, he worked on delveloping methods for single molecule measurement techniques and creating ultrasensetive assays for tumor DNA.

Career

Since 2013, Anders Ståhlberg has been a Principal Investigator at the Sahlgrenska Cancer center and Sahlgrenska University Hospital. From 2013 to 2017, he served as a Group Leader in the Department of Pathology. In 2017, he began leading the Translational Genomics Platform, an initiative to integrate advanced liquid biopsy techniques into clinical practice.
In June 2022, he was appointed Professor of Clinical Genomics at the University of Gothenburg's Sahlgrenska Academy. His research focuses on biomarers for early cancer detection and monitoting treatment response.

Research

Ståhlberg's research group has developed techniques for detecting circulating tumor DNA in blood and urine. These methods use DNA barcoding and unique molecular identifiers to identify mutations with low allele frequencies. The aim of these techniques is to enable the early detection of remaining tumor burden, track treatment responses, and identify relapses.Single-cell and Single-molecule Quantification
A part of his research is dedicated to analyzing gene expression at the single-cell level, using methods such as qPCR-based workflows. His collaboration with Mikael Kubista has focused on the application of single-cell gene expression profiling for both diagnostics and research.Sarcoma Biology and Fusion-driven Oncology
Stahlberg also examines the molecular mechanisms of sarcomas and fusion oncogene drivers. The research aims to develop precision diagnostics and targeted treatment options, particularly for pediatric sarcomas.

Selected publications

  1. Digital sequencing improved by structured UMIz-enabling error corrected ctDNA detection in Genome Biology, 2025
  2. TERT promoter mutation mechanisms in Nature Communications, Nov 2024.
  3. Myxiodliposarcoma tumor micro environment in J Transl Med, April 2024.
  4. Digital RNA Sequencing with UMIs for ultra-sensitive RNA mutation detection in Communications Biology, March 2024.
  5. UMI error correction software: UMI Analyzer and UMI Error Correct in Clinical Chemistry, Nov 2022.

TATAA Biocenter

In 2001, Stahlberg co-founded TATAA Biocenter with Mikael Kubista and Neven Zoric. Under the leadership of Zoric and Kubista, supported by Ståhlberg and other academic experts like Michael Pfaffl and Stephen Bustin, TATAA became the world’s leading provider of qPCR training and Europe’s largest qPCR service laboratory. TATAA was the first in Europe to obtain flexible ISO 17025 accreditation and received several industry recognitions, including the Frost & Sullivan Award for Customer Value Leadership and the title of Best Nucleic Acid Analysis Service Provider – Europe by Global Health & Pharma. It was listed on Sweden’s Technology Fast 50 by Deloitte. In 2021 TATAA was the first laboratory in Europe to offer COVID-19 testing.
In 2021 TATAA accepted financing from Care Equity to expand into GLP/GCP-regulated molecular services for the pharmaceutical industry, with a focus on Cell and Gene Therapies. However, due to Care Equity General Partner Peter Batesko’s refusal to register ownership, the founders lost the company without compensation.

Awards and Collaborations

Andres Ståhlberg has been involved in several projects and collaborations, and has received notable funding for his work:
  • He received funding from Swelife, vinnova, and Medtech4Health for a project focused on developing a graphene-CRISPR chip for the rapid detection of mutuations in liquid biopsies. This Project is a collaboration with scientists from Chalmers University and Gothenburg.
  • In 2003, he co-founded TATAA Biocenter alongside Mikael Kubista and Neven Zoric. In 2023, his stake in the company was revoked.
  • He established SiMSen Diagnostics in 2020 with Professor Tony Godfery, Mikael Kubista, and GU Ventures, with the purpose of providing circulating tumor DNA analysis.
  • In 2023, he was awarded a two-year grant from the swedish Childhood Cancer Fund to research the use of circulating tumor DNA for assessing treatment response in children with sarcoma.